Uses
CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. CTEXLI is a bile acid indicated for treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Source: US FDA prescribing information
- Presentations
- 2
- Brands
- 2
- Manufacturers
- 2
- Available from stock
- 0
Chenodiol is a bile acid indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. It is available as tablets for oral use. MedsAcross supplies Chenodiol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Bile Acid
- ATC classification
- A05AA01 Chenodiol · Liver and bile treatments, subgroup A05A, subgroup A05AA
- US FDA first approval
- 28 July 1983
- EU status
- Not recorded
- Orphan designation
- Yes
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Tablet
- Identifiers
- UNII 0GEI24LG0JRxCUI 2323CAS 474-25-9DrugBank DB06777Q419028
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Endogenous chenodiol (chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene. CTEXLI may act to replace deficient levels of the endogenous bile acid chenodeoxycholic acid in patients with CTX. Increased chenodiol levels in the enterohepatic bile acid pool restore the activation of farnesoid X receptor (FXR) and downregulate CYP7A1 leading to suppression and reduction of atypical bile acids and bile alcohols including cholestanol and 23S-pentol.
Source: US FDA prescribing information
Dosing overview
• Before initiating CTEXLI, obtain baseline liver transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and total bilirubin levels in all patients. • The recommended dosage is 250 mg orally three times daily.
Source: US FDA prescribing information
Contraindications
None. None.
Source: US FDA prescribing information
Warnings and precautions
Hepatotoxicity: Obtain baseline liver transaminase and total bilirubin levels in all patients and monitor yearly and as clinically indicated. Interrupt treatment until the levels have returned to baseline values. For persistent or recurrent liver test abnormalities, consider discontinuing CTEXLI.
Source: US FDA prescribing information
Side effects
The following clinically significant adverse reaction is described elsewhere in the labeling: • Hepatotoxicity The most common adverse reactions (incidence > 14%) are diarrhea, headache, abdominal pain, constipation, hypertension, muscular weakness, and upper respiratory tract infection.
Source: US FDA prescribing information
Interactions
• Bile acid sequestering agents and aluminum-based antacids: Avoid concomitant use with CTEXLI. • Coumarin and its derivatives: Monitor prothrombin time and adjust dosage accordingly.
Source: US FDA prescribing information
Storage
Store CTEXLI at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
2 presentations of Chenodiol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Chenodal 250 mg tabletOral | Travere Therapeutics | US FDA | Available on request |
| Ctexli 250 mg tabletOral | Mirum Pharmaceuticals | US FDA | Available on request |
Brands by market
2 brand names across 1 markets.
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 28 July 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Chenodiol in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Chenodiol available for export from India?
Yes, on request. MedsAcross lists 2 presentations of Chenodiol and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Chenodiol have?
The catalogue lists 2 brand names for Chenodiol, including Chenodal, Ctexli.
Is Chenodiol approved by the US FDA?
Yes. The US FDA first approved Chenodiol on 28 July 1983, according to Drugs@FDA.
Does Chenodiol need cold chain shipping?
No listed presentation of Chenodiol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Chenodiol in?
Chenodiol is classified under ATC code A05AA01 (Chenodiol).
References
- CTEXLI prescribing information (Mirum Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 16 December 2025
Request Chenodiol for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.